Infectious Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others), By End Use (Hospitals, Clinics, Others), By Region, and By Competition, 2019-2029F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationInfectious Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others), By End Use (Hospitals, Clinics, Others), By Region, and By Competition, 2019-2029F
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 67.04 billion |
| Market Size (2029) | USD 97.88 billion |
| CAGR (2024-2029) | 7.00% |
| Fastest Growing Segment | Hospitals |
| Largest Market | North America |
Market Overview
Global Infectious Disease Therapeutics Market was valued at USD 67.04 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.00% through 2029. The Global Infectious Disease Therapeutics Market refers to the pharmaceutical and biotechnological industry's efforts to develop and market drugs and treatments for infectious diseases.
Key Market Drivers
Rising Disease Burden
The Global Infectious Disease Therapeutics Market has been on an upward trajectory in recent years, largely fueled by the escalating burden of infectious diseases worldwide. A persistent and increasing disease burden is not only a global health concern but also a driving force behind the growth of the infectious disease therapeutics market.
Advancements in Biotechnology
In recent years, the Global Infectious Disease Therapeutics Market has witnessed a remarkable surge in growth, largely propelled by advances in biotechnology. Biotechnology innovations have revolutionized the way we understand, diagnose, and treat infectious diseases.
Biotechnology has enabled the development of gene-based therapies that hold great promise in treating infectious diseases. Techniques like gene editing and gene therapy can target and modify the genetic material of pathogens, rendering them less harmful or susceptible to treatment. These innovative therapies have the potential to revolutionize infectious disease treatment in the coming years.
Vaccines and Immunotherapies
In the ever-evolving landscape of global healthcare, vaccines and immunotherapies have emerged as indispensable tools in the battle against infectious diseases. These two pillars of preventive and therapeutic interventions play a pivotal role in shaping the growth of the Global Infectious Disease Therapeutics Market.
Monoclonal antibodies, a subset of immunotherapies, have garnered attention for their effectiveness in treating infectious diseases. These laboratory-engineered antibodies are designed to target specific pathogens, offering a powerful therapeutic option for patients. Monoclonal antibodies, as seen in the response to COVID-19, have the potential to revolutionize infectious disease treatment and boost the market.
Pandemic Preparedness
Pandemics, such as the COVID-19 crisis, have a profound impact on public health, economies, and global stability. As a result, pandemic preparedness has become a paramount concern, and it is directly linked to the growth of the Global Infectious Disease Therapeutics Market.
Preparedness includes the development of vaccines, as vaccines are a vital tool in controlling the spread of infectious diseases. The COVID-19 vaccine development and distribution efforts serve as a case in point, demonstrating the pivotal role vaccines play in pandemic preparedness. These endeavors stimulate growth in the vaccine market within the infectious disease therapeutics sector.
Key Market Challenges
Antimicrobial Resistance (AMR)
Antimicrobial Resistance (AMR) poses a significant challenge to the Global Infectious Disease Therapeutics Market, threatening the effectiveness of existing treatments and necessitating the development of novel strategies. Bacteria, viruses, and parasites are evolving resistance to commonly used antimicrobial drugs, rendering them less effective or even ineffective in treating infections. This phenomenon not only complicates patient care but also increases healthcare costs and mortality rates globally. T
Emerging and Re-emerging Infectious Diseases
Emerging and re-emerging infectious diseases present a significant challenge to the Global Infectious Disease Therapeutics Market. These diseases, such as Zika virus, Ebola virus, and the novel coronavirus responsible for COVID-19, continuously challenge public health systems and therapeutic development efforts worldwide. The rapid spread of such diseases underscores the critical need for timely and effective therapeutic interventions.
Key Market Trends
Growing Demand for Antiviral Therapies
The Global Infectious Disease Therapeutics Market is experiencing a notable surge in demand for antiviral therapies, driven by several factors contributing to the increasing prevalence of viral infections worldwide. Viral diseases such as HIV/AIDS, hepatitis, influenza, and emerging viruses like Zika and coronaviruses pose significant public health challenges, necessitating effective treatment options. The key
Rising Personalized Medicine
Personalized medicine is emerging as a significant trend in the Global Infectious Disease Therapeutics Market, revolutionizing the approach to treating infectious diseases. This approach tailors medical treatments to the individual characteristics of each patient, including their genetic makeup, immune response, and disease susceptibility. In the context of infectious diseases, personalized medicine offers several advantages and opportunities. The
Segmental Insights
Disease Type Insights
Based on disease type, the HIV sector dominated the market in 2023. This was primarily due to several key factors, including the growing prevalence of HIV, increased funding for HIV patient support, the wider distribution of free HIV self-test kits in African nations, and global awareness campaigns. The World Health Organization (WHO) has recognized HIV as a significant global public health concern, with an ongoing worldwide transmission that has claimed 40.4 million lives.
The HPV sector is projected to experience the highest CAGR during the forecast period. This growth can be attributed to the increasing prevalence of HPV and the affordability of drugs used to treat this infection. According to WHO, HPV is the most common sexually transmitted infection, affecting a large proportion of sexually active individuals at some point in their lives. Although there is no cure for HPV, its symptoms, such as genital warts, can be managed with various anti-infective drugs. In January 2023, India's Serum Institute of India launched 'CERVAVAC,' the first domestically produced Quadrivalent Human Papillomavirus vaccine, in collaboration with the institute, DBT, BIRAC, and the Bill and Melinda Gates Foundation.
End Use Insights
Based on end use, the hospital sector claimed the largest share of revenue. A significant driver of market growth is the increasing volume of emergency hospital visits related to infectious diseases. Hospitals are particularly attractive because they offer reimbursement options and services through insurance providers, creating favorable growth prospects for this segment. These facilities reduce the need for patients to seek care at multiple locations, thereby enhancing the value proposition of the hospital sector. According to the Centers for Disease Control and Prevention (CDC), the 2021–2022 influenza season witnessed 9 million illnesses, 4 million doctor visits, 10,000 hospitalizations, and 5,000 fatalities.
Meanwhile, the clinics segment is expected to experience the highest CAGR during the forecast period. This can be attributed to the growing demand for outpatient care, the availability of advanced diagnostic and therapeutic resources, and increased public awareness of preventive measures. Clinics offer a range of services for infectious disease patients, including screening, testing, vaccination, counseling, and treatment. They also provide access to specialized care for complex and rare infections like HIV/AIDS, tuberculosis, hepatitis, and COVID-19. Clinics actively participate in clinical trials and research endeavors aimed at evaluating the safety and effectiveness of new drugs and vaccines for infectious diseases, contributing to the growth of this sector.
Download Free Sample Report
Regional Insights
Based on region, North America emerged as the leading market for infectious disease therapeutics market in 2023. This was primarily driven by the growing prevalence of such disorders and the favorable reimbursement landscape in the region. The presence of numerous manufacturers in the United States and an increasing number of clinical trials aimed at developing new treatment drugs played a significant role in securing a substantial market share for North America. Key factors contributing to the market's growth include the rising rates of infectious disease diagnosis and treatment, coupled with increased funding initiatives to support the development of new drugs. Notably, the Centers for Disease Control and Prevention reported 41,917 deaths in the U.S. due to influenza and pneumonia in 2021.
Conversely, Asia Pacific is projected to exhibit the highest CAGR during the forecast period. This growth can be attributed to the region's high prevalence of infectious diseases such as HIV, malaria, and tuberculosis, along with an increasing incidence of these conditions. There is a notable rise in expenditures dedicated to the prevention and diagnosis of infectious diseases in the region. Governments in various countries are increasingly focusing on infection prevention and allocating funds to promote the adoption of treatments for infectious diseases, further propelling market growth. Notably, in June 2023, INVEX Health announced the launch of India's first oral HIV self-test, the saliva-based Morcheck test, which checks for both HIV types 1 and 2.
It's worth noting that a significant proportion of individuals suffering from these infections reside in Africa. The WHO African Region shoulders a substantial burden of malaria globally, with 95% of cases and 96% of malaria-related deaths in 2021. Children under the age of 5 accounted for 80% of these fatalities. Various initiatives focusing on disease prevention are being implemented in the region, and government, private, and nonprofit organizations are actively involved in enhancing the management of these diseases. For instance, Novartis provides free medications to malaria patients in the African region.
Recent Developments
- In June 2022, NRG Therapeutics achieved a significant milestone by securing $18.3 million in Series A financing. This funding infusion will propel the company's efforts in advancing therapeutic solutions targeting mitochondria, a crucial cellular component, to combat neurodegenerative disorders. With a focus on conditions such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS), NRG Therapeutics aims to pioneer innovative treatments that address the underlying mechanisms of these debilitating diseases. The Series A financing not only validates the potential of NRG Therapeutics' approach but also underscores investor confidence in the promising trajectory of their research and development endeavors.
Key Market Players
- Novartis AG
- Gilead Sciences Inc
- GSK PLC
- Johnson & Johnson Innovative Medicine
- FHoffmann-La Roche AG
- BioCryst Pharmaceuticals Inc
- Merck & Co Inc
- Boehringer Ingelheim International GmbH
| By Disease Type | By End Use | By Region |
|
|
|
Report Scope
In this report, the Global Infectious Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Infectious Disease Therapeutics Market, By Disease Type
o
o
o
o
o
o
o
- Infectious Disease Therapeutics Market, By End Use
o
o
o
- Infectious Disease Therapeutics Market, By Region
o
o
o
o
o
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Infectious Disease Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy